Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis

Figure 3

(a) Comparison of post-event overall survival by ASCT after first relapse or progression in patients with POD24. (b) Comparison of post-event overall survival by participation in clinical trials. (c) Comparison of post-event overall survival by participation in clinical trials in HBsAg-positive or anti-HBc antibody-positive patients.ASCT: Autologous stem cell transplantation; POD24: progression of disease within 24 months; HBsAg: hepatitis B surface antigen; anti-HBc antibody; hepatitis B core antibody.

(a)

(b)

(c)